Copper containing intra-uterine devices versus depot progestogens for contraception

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 9, 2010, Pages

  Hofmeyr, G Justus ^a   Singata, Mandisa ^a   Lawrie, Theresa A ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

CHEMICALLY INDUCED DISORDER; CONTRACEPTION; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; METHODOLOGY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; INTRAUTERINE DEVICES, COPPER; MEDROXYPROGESTERONE ACETATE; PREGNANCY; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77954968345     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007043.pub2     Document Type: Review

References (62)

1. Feldblum PJ, Caraway J, Bahamondes L, El-Shafei M, Quan Ha D, Morales Eet al. Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrolment, continuation and disease ascertainment. Contraception 2005;72(3):187-91.
2. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. American Journal of Obstetrics and Gynecology 2007 Aug;197(2):144.e1-8.
3. Altunyurt S, Demir N, Posaci C. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. European Journal of Obstetrics, Gynecololgy and Reproductive Biology 2003;107(1):81-4.
4. All Party Parliamentary Group on Population Development and Reproductive Health Development Goals (HMSO, London, 2007), for the report and oral and written evidence, see www.appgpopdevrh.org.uk. Return of the Population Growth Factor: Its Impact on the Millennium Development Goals. HMSO. London, 2007.
5. Barnhart KT, Sammel MD, Gracia CR, Chittams J, Hummel AC, Shaunik A. Risk factors for ectopic pregnancy in women with symptomatic first-trimester pregnancies. Fertil Steril 2006;86(1):36-43.
6. Barrett J, Buckley C. Constrained contraceptive choice: IUD prevalence in Uzbekistan. Int Fam Plan Perspect 2007;33:50-7.
7. Bhathena RK, Guillebaud J. Contraception for the older woman: an update. Climacteric 2006;9:264-76.
8. Bounds W, Hutt S, Kubba A, Cooper K, Guillebaud J, Newman GB. Randomised comparative study in 217 women of three disposable plastic IUCD thread retrievers. British Journal of Obstetrics and Gynaecology 1992;99:915-9.
9. Campbell M, Cleland J, Ezeh A, Prata N. Return of the Population Growth Factor. Science 2007;315:1501.
10. Campbell SJ, Cropsey KL, Matthews CA. Intrauterine device use in a high-risk population: experience from an urban university clinic. American Journal of Obstetrics and Gynecology 2007;197(2):193e.1-6.
11. Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. Contraception 2007;75 (6 Suppl):S60-S69.
12. Draper BH, Morroni C, Hoffman M, Smit J, Beksinska M, Hapgood J, et al. Depot medroxyprogesterone versus Norethisterone oenanthate for long-acting progestogenic contraception. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: CD005214]
13. El-Hefnawy AS, El-Nahas AR, Osman Y, Bazeed MA. Urinary complications of migrated intrauterine contraceptive device. International Urogynecology Journal and Pelvic Floor Dysfunction 2007;ePub:ePub.
14. Feldblum PJ, Caraway J, Bahamondes L, El-Shafei M, Quan Ha D, Morales E, et al. Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment. Contraception 2005;72(3):187-91.
15. French R, Van Vliet H, Cowan F, Mansour D, Morris S, Hughes D, et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: CD001776]
16. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. American Journal of Epidemiology 1994;140:290-6.
17. Grimes DA, Schulz FK. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: CD001327]
18. Grimes D, Schulz K, Van Vliet H, Stanwood N. Immediate post-partum insertion of intrauterine devices. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: CD003036]
19. Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: CD001777]
20. Güney M, Oral B, Mungan T. Efficacy of intrauterine lidocaine for removal of a "lost" intrauterine device: a randomized, controlled trial. Obstetrics and Gynecology 2006;108(1):119-23.
21. Helmerhorst FM, Belfield T, Kulier R, Maitra N, O'Brien P, Grimes DA. The Cochrane Fertility Regulation Group: synthesizing the best evidence about family planning. Contraception 2006;74(4):280-6.
22. Hong R, Montana L, Mishra V. Family planning services quality as a determinant of use of IUD in Egypt. BMC Health Serv Res 2006;6(1):79.
23. Hubacher D, Reyes V, Lillo S, Pierre-Louis B, Zepeda A, Chen PL, et al. Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. Hum Reprod 2006;21(6):1467-72.
24. Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception 2007;75 (6 Suppl):S8-S11.
25. Kulier R, Helmerhorst F, O'Brien P, Usher-Patel M, d'Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: CD005347]
26. Lalos O, Nilsson B. Dysmenorrhea in women with intrauterine contraceptive device, treatment with a prostaglandin synthetase inhibitor, naproxen. International Journal of Gynaecology and Obstetrics 1983;21:33-7.
27. Lawrie TA, Hofmeyr GJ, De Jager M, Berk M, Paiker J, Viljoen E. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. British Journal of Obstetrics and Gynaecology 1998;105:1082-90.
28. Li Y, Zhou L, Coulter D, Gao E, Sun Z, Liu Y, et al. Prospective cohort study of the association between use of low-dose oral contraceptives and stroke in Chinese women. Pharmacoepidemiology and Drug Safety 2006;15(10):726-34.
29. Lin X, Gao ES, Li D, Zhang M, Dou LX, Yuan W. Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstetricia et Gynecologica Scandinavica 2007;86:1126-9.
30. Meirik O. Intrauterine devices - upper and lower genital tract infections. Contraception 2007;75 (6 Suppl):S41-S47.
31. Mittal S. Contraception after medical abortion. Contraception 2006;74(1):56-60.
32. Mohllajee A, Curtis K, Peterson H. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection?. Contraception February 2006;73(2):145-53.
33. Moreau C, Trussell J, Rodriguez G, Bajos N, Bouyer J. Contraceptive failure rates in France: results from a population-based survey. Human Reprodroduction 2007;22(9):2422-7.
34. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al. Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study Group. Hormonal contraception and the risk of HIV acquisition. AIDS 2007;21(1):85-95.
35. Morrison CS, Norris Turner A, Jones LB. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Practice & Research Clinical Obstetrics and Gynaecology 2009;23:263-84.
36. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. International Journal of Epidemiology 2007;36:166-74.
37. Mäkäräinen L, Ylikorkala O. Ibuprofen prevents IUCD-induced increases in menstrual blood loss. British Journal of Obstetrics and Gynaecology 1986;93:285-8.
38. O'Brien PA, Marfleet C. Frameless versus classical intrauterine device for contraception. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: CD003282]
39. Ortayli N. Progestogen-only injectable contraceptives and bone health. IPPF Bulletin 2006;40:5-6.
40. Osei I, Birungi H, Addico G, Askew I, Gyapong JO. What happened to the IUD in Ghana?. African Journal of Reproductive Health 2005;9(2):76-91.
41. Otero-Flores JB, Guerrero-Carreno FJ, Vazquez-Estrada LA. A comparative randomized study of three different IUDs in nulliparous Mexican women. Contraception 2003;67(4):273-6.
42. Paladine HL, Blenning CE, Judkins DZ, Mittal S. What are contraindications to IUDs?. Journal of Family Practice 2006;55(8):726-9.
43. Pap-Akeson M, Solheim F, Thorbert G, Akerlund M. Genital tract infections associated with the intrauterine contraceptive device can be reduced by inserting the threads into the uterine cavity. British Journal of Obstetrics and Gynaecology 1992;99:676-9.
44. Potts DM, Champion CB, Kozuh-Novak M, Alvarez-Sanchez F, Santiso-Galvez R, Tacla X, et al. IUDs and PID: a comparative trial of strings versus stringless devices. Advances in Contraception 1991;7(2-3):321-40.
45. Quercia R, Bani Sadr F, Cortez A, Arlet G, Pialoux G. Genital tract actinomycosis caused by Actimyces israelii. Médicine et Maladies Infectieuses 2006;36(7):393-5.
46. Salem RM. New attention to the IUD: expanding women's contraceptive options to meet their needs. Population and Reproductive Health Bulletin 2006;Feb(7):1-26.
47. Sekadde-Kigondu C, Mwathe EG, Ruminjo JK, Nichols D, Katz K, Jessencky K, et al. Acceptability and discontinuation of Depo-Provera, IUCD and combined pill in Kenya. East African Medical Journal 1996;73:786-94.
48. Shah NM, Shah MA, Chowdhury RI, Menon I. Reasons and correlates of contraceptive discontinuation in Kuwait. European Journal of Contraception and Reproductive Health Care 2007;12:260-8.
49. Sinei SK, Schulz KF, Lamptey PR, Grimes DA, Mati JK, Rosenthal SM, et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. British Journal of Obstetrics and Gynaecology 1990;97(5):412-9.
50. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception 2007;75 (6 Suppl):S70-S75.
51. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. American Journal of Obstetrics and Gynecology 2007;197(2):144.e1-8.
52. Stringer EM, Levy J, Sinkala M, Chi BH, Matongo I, Chintu N, et al. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS 2009;23(11):1377-82.
53. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004;69(5):407-12.
54. Sääv I, Aronsson A, Marions L, Stephansson O, Gemzell-Danielsson K. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Human Reproduction 2007;ePub:ePub.
55. Tao MH, Xu WH, Zheng W, Zhang ZF, Gao YT, Ruan ZX, et al. Oral contraceptive and IUD use and endometrial cancer: A population-based case-control study in Shanghai, China. International Journal of Cancer 2006;119(9):2142-7.
56. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Human Reproduction 2006;21(10):2612-6.
57. Trussell J. Contraceptive Efficacy. In: Hatcher RA, Trussell J, Stewart F, Nelson A, Cates W, Guest F, Kowal D editor(s). Contraceptive Technology. Eighteenth Revised. New York: Ardent Media, 2004.
58. Villar J, Carroli G, Belizan JM. Predictive ability of meta-analysis of randomised control trials. Lancet 1995;345:772-6.
59. Department of Reproductive Health, World Health Organization. Medical eligibility criteria for contraceptive use. WHO 2009.
60. Wildemeersch D. New frameless and framed intrauterine devices and systems - an overview. Contraception 2007;75 (6 Suppl):S82-S92.
61. Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. British Journal of Obstetrics and Gynaecology 1983;90:78-83.
62. Youssef RM. Contraception use and probability of continuation: community-based survey of women in southern Jordan. East Mediterranean Health Journal 2005;11(4):545-58.